欢迎访问《现代生物医学进展》编辑部！

目的：探讨曲妥珠单抗联合多西紫杉醇在HER-2 阳性晚期乳腺癌中的应用。方法：收取2010 年2 月至2016 年1 月我院收治的82 例HER-2 阳性晚期乳腺癌患者作为研究对象，根据不同治疗方案分为观察组及对照组。观察组43 例患者给予曲妥珠单抗联合多西紫杉醇治疗，多西紫杉醇以3 周为1 个周期，连续用药4 个周期，曲妥珠单抗连续使用8周~52 周。对照组39 例患者只给予曲妥珠单抗单药治疗。对两组患者临床疗效、临床受益反应指数以及不良反应发生情况进行观察与比较。结果：观察组总有效率（60.47 %）高于对照组（43.59 %），但差异无统计学意义（P>0.05）。观察组疾病控制率（90.70 %）显著高于对照组（71.79 %），差异有统计学意义（P<0.05）。观察组临床受益反应有效率（76.74 %）显著高于对照组（41.03 %），差异有统计学意义（P<0.05）。两组患者不良反应无显著差异（P>0.05）。结论：曲妥珠单抗联合多西紫杉醇对于HER-2 阳性晚期乳腺癌有较好的临床疗效及安全性，患者临床受益高。

英文摘要:

Objective:To explore the application of trastuzumab combined docetaxel in treatment of HER-2 positive advanced breast cancer.Methods:82 patients with HER-2 positive advanced breast cancer accepted in our hospital from February 2010 to January 2016 were selected and divided into observation group and control group according to different methods of treatment. 43 patients in observation group were given trastuzumab for 8 weeks to 52 weeks combined docetaxel for 4 periods (3 weeks a period), and 39 patients in control group were given trastuzumab only. Then the clinical efficacy, clinical benefit response rate and adverse reaction rate of two groups were observed and compared.Results:The total efficacy of observation group (60.47 %) was higher than that of control group (43.59 %) without statistically significance (P>0.05). The diseases control rate of observation group (90.70 %) was obviously higher than that of control group (71.79 %) with statistically difference (P<0.05). The clinical benefit response rate of observation group (76.74 %) was higher than that of control group (41.03 %) with statistically significance (P<0.05). The rate of adverse reaction of two groups had no difference (P>0.05).Conclusion:Trastuzumab combined docetaxel has good efficacy and safety in treatment of HER-2 positive advanced breast cancer, and it can also improve the clinical benefit response rate.

查看全文查看/发表评论下载PDF阅读器

关闭